Extraskeletal actions of vitamin D

Annals of the New York Academy of Sciences

Volumn 1376, Issue 1, 2016, Pages 29-52

  Bikle, Daniel D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; cardiovascular; CYP27B1; immune system; skin; vitamin D

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; ADIPOCYTE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE CELL; BONE TISSUE; BREAST CANCER; COLORECTAL CANCER; DNA REPAIR; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INNATE IMMUNITY; METASTASIS INHIBITION; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON MELANOMA SKIN CANCER; NONHUMAN; OBESITY; PANCREAS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKELETON; SKIN; SKIN DISEASE; VITAMIN D METABOLISM; ANIMAL; BIOLOGICAL MODEL; BONE; CLINICAL TRIAL (TOPIC); DISEASES; DRUG EFFECTS;

ANIMALS; BONE AND BONES; CLINICAL TRIALS AS TOPIC; DISEASE; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; VITAMIN D;

EID: 85008946274     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13219     Document Type: Review

References (287)

1. Bikle, D.D. 1992. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr. Rev. 13: 765–784.
2. Bikle, D.D. 2009. Extra renal synthesis of 1,25 dihydroxyvitamin D and its health implications. Clin. Rev. Bone Miner. Metab. 7: 114–125.
3. Skorija, K., M. Cox, J.M. Sisk, et al. 2005. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol. Endocrinol. 19: 855–862.
4. Slominski, A.T., T.K. Kim, W. Li, et al. 2014. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J. Steroid Biochem. Mol. Biol. 144(Pt. A): 28–39.
5. Pike, J.W. 2011. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol. Cell. Endocrinol. 347: 3–10.
6. Xie, Z. & D.D. Bikle. 1997. Cloning of the human phospholipase C-γ1 promoter and identification of a DR6-type vitamin D-responsive element. J. Biol. Chem. 272: 6573–6577.
7. 3-MARRS (membrane-associated, rapid response steroid-binding) receptor/PDIA3/Erp57. J. Biol. Chem. 285: 31859–31866.
8. 3. Endocrinology 115: 1476–1483.
9. 3 in osteosarcoma cells. J. Cell. Biochem. 99: 995–1000.
10. Carlberg, C. 2014. Genome-wide (over)view on the actions of vitamin D. Front. Physiol. 5: 167.
11. Carlberg, C., S. Seuter & S. Heikkinen. 2012. The first genome-wide view of vitamin D receptor locations and their mechanistic implications. Anticancer Res. 32: 271–282.
12. Ramagopalan, S.V., A. Heger, A.J. Berlanga, et al. 2010. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20: 1352–1360.
13. Oda, Y., C. Sihlbom, R.J. Chalkley, et al. 2003. Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation. Mol. Endocrinol. 17: 2329–2339.
14. Saccone, D., F. Asani & L. Bornman. 2015. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene 561: 171–180.
15. Narvaez, C.J., D. Matthews, E. LaPorta, et al. 2014. The impact of vitamin D in breast cancer: genomics, pathways, metabolism. Front. Physiol. 5: 213.
16. Santagata, S., A. Thakkar, A. Ergonul, et al. 2014. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J. Clin. Invest. 124: 859–870.
17. Matusiak, D. & R.V. Benya. 2007. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J. Histochem. Cytochem. 55: 1257–1264.
18. Brozek, W., T. Manhardt, E. Kallay, et al. 2012. Relative expression of vitamin D hydroxylases, CYP27B1 and CYP24A1, and of cyclooxygenase-2 and heterogeneity of human colorectal cancer in relation to age, gender, tumor location, and malignancy: results from factor and cluster analysis. Cancers 4: 763–776.
19. 3-based therapies. FASEB J. 28: 364–372.
20. Albertson, D.G., B. Ylstra, R. Segraves, et al. 2000. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25: 144–146.
21. Borkowski, R., L. Du, Z. Zhao, et al. 2015. Genetic mutation of p53 and suppression of the miR-17 approximately 92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D signaling. Cancer Res. 75: 666–675.
22. Christakos, S., P. Dhawan, A. Verstuyf, et al. 2016. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev. 96: 365–408.
23. 3 by directly targeting E2F3 in gastric cancer cells. Oncotarget 6: 7675–7685.
24. 3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 71: 6230–6239.
25. 3/VDR protection against skin cancer formation. Exp. Dermatol. 23: 147–150.
26. 3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 121: 103–109.
27. 3 in human colon cancer cells. Cancer Res. 63: 7799–7806.
28. Liu, G., X. Hu & S. Chakrabarty. 2010. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int. J. Cancer 126: 631–639.
29. An, B.S., L.E. Tavera-Mendoza, V. Dimitrov, et al. 2010. Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol. Cell. Biol. 30: 4890–4900.
30. Meyer, M.B., P.D. Goetsch & J.W. Pike. 2012. VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol. Endocrinol. 26: 37–51.
31. Colston, K.W., C.M. Perks, S.P. Xie & J.M. Holly. 1998. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J. Mol. Endocrinol. 20: 157–162.
32. 3 and its analog EB1089. Int. J. Oncol. 13: 137–143.
33. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92: 131–141.
34. Swami, S., N. Raghavachari, U.R. Muller, et al. 2003. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80: 49–62.
35. 3 analog-induced growth inhibition in breast cells. J. Cell. Physiol. 188: 383–393.
36. Aszterbaum, M., A. Rothman, R.L. Johnson, et al. 1998. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110: 885–888.
37. Teichert, A.E., H. Elalieh, P.M. Elias, et al. 2011. Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. J. Invest. Dermatol. 131: 2289–2297.
38. 3 in breast cancer cells. J. Mol. Endocrinol. 35: 117–133.
39. Cordero, J.B., M. Cozzolino, Y. Lu, et al. 2002. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem. 277: 38965–38971.
40. Byers, S.W., T. Rowlands, M. Beildeck & Y.S. Bong. 2011. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev. Endocr. Metab. Disord. 13: 31–38.
41. Bikle, D.D. 2011. The vitamin D receptor: a tumor suppressor in skin. Discov. Med. 11: 7–17.
42. 3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28: 1877–1884.
43. 3. Oncogene 27: 4467–4477.
44. 3 on colon cancer cells depend on RhoA-ROCK-p38MAPK-MSK signaling. J. Steroid Biochem. Mol. Biol. 121: 355–361.
45. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60: 2304–2312.
46. Pan, L., A.F. Matloob, J. Du, et al. 2010. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J. 277: 989–999.
47. 3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann. Hematol. 89: 1–7.
48. Weitsman, G.E., A. Ravid, U.A. Liberman & R. Koren. 2003. Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann. N.Y. Acad. Sci. 1010: 437–440.
49. 2: mitochondria as a convergence point in the death pathway. Free Radic. Biol. Med. 39: 266–278.
50. 2+ signaling in breast cancer. Anticancer Res. 32: 299–302.
51. Hoyer-Hansen, M., L. Bastholm, I.S. Mathiasen, et al. 2005. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 12: 1297–1309.
52. Freeman, S.E., H. Hacham, R.W. Gange, et al. 1989. Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. Proc. Natl. Acad. Sci. U.S.A. 86: 5605–5609.
53. Besaratinia, A., T.W. Synold, H.H. Chen, et al. 2005. DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc. Natl. Acad. Sci. U.S.A. 102: 10058–10063.
54. Hussein, M.R. 2005. Ultraviolet radiation and skin cancer: molecular mechanisms. J. Cutan. Pathol. 32: 191–205.
55. Demetriou, S.K., K. Ona-Vu, A.E. Teichert, et al. 2012. Vitamin D receptor mediates DNA repair and is UV inducible in intact epidermis but not in cultured keratinocytes. J. Invest. Dermatol. 132: 2097–2100.
56. Ooi, L.L., H. Zhou, R. Kalak, et al. 2010. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 70: 1835–1844.
57. Kallay, E., P. Pietschmann, S. Toyokuni, et al. 2001. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429–1435.
58. Fedirko, V., R.M. Bostick, Q. Long, et al. 2010. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 19: 280–291.
59. Moll, P.R., V. Sander, A.M. Frischauf & K. Richter. 2007. Expression profiling of vitamin D treated primary human keratinocytes. J. Cell. Biochem. 100: 574–592.
60. 3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15: 1127–1139.
61. 3 against oxidative stress in nonmalignant human prostate epithelial cells. Int. J. Cancer 122: 2699–2706.
62. 3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther. 6: 1433–1439.
63. 3 inhibits angiogenesis in vitro and in vivo. Circ. Res. 87: 214–220.
64. 3 decreases human prostate cancer cell adhesion and migration. Mol. Cell. Endocrinol. 164: 133–143.
65. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27: 1883–1893.
66. Vanoirbeek, E., G. Eelen, L. Verlinden, et al. 2014. PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D. Oncogene 33: 1904–1911.
67. Liu, W., M. Guo, S. Ezzat & S.L. Asa. 2011. Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Lab. Invest. 91: 147–156.
68. Newmark, H.L., K. Yang, N. Kurihara, et al. 2009. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 30: 88–92.
69. Froicu, M., V. Weaver, T.A. Wynn, et al. 2003. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 7: 2386–2392.
70. Kong, J., Z. Zhang, M.W. Musch, et al. 2008. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G208–G216.
71. Murillo, G., V. Nagpal, N. Tiwari, et al. 2003. Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J. Steroid Biochem. Mol. Biol. 121: 403–407.
72. 1638N/+ mice. J. Nutr. 138: 1658–1663.
73. Xu, H., G.H. Posner, M. Stevenson & F.C. Campbell. 2010. Apc(min) modulation of vitamin D secosteroid growth control. Carcinogenesis 31: 1434–1441.
74. Zheng, W., K.E. Wong, Z. Zhang, et al. 2011. Inactivation of the vitamin D receptor in APC(min/+) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth. Int. J. Cancer 130: 10–19.
75. min mouse. Cancer Res. 62: 741–746.
76. Lipkin, M. & H.L. Newmark. 1999. Vitamin D, calcium and prevention of breast cancer: a review. J. Am. Coll. Nutr. 18: 392S–397S.
77. Zinser, G.M. & J. Welsh. 2004. Effect of vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. J. Steroid Biochem. Mol. Biol. 89–90: 433–436.
78. 3 analog, EB1089. Endocrinology 139: 2102–2110.
79. El Abdaimi, K., N. Dion, V. Papavasiliou, et al. 2000. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 60: 4412–4418.
80. Bhatia, V., M.K. Saini, X. Shen, et al. 2009. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8: 1787–1798.
81. Zheng, Y., H. Zhou, L.L. Ooi, et al. 2011. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 71: 1012–1021.
82. Mordan-McCombs, S., T. Brown, W.L. Wang, et al. 2010. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J. Steroid Biochem. Mol. Biol. 121: 368–371.
83. Krishnan, A.V., D.L. Trump, C.S. Johnson & D. Feldman. 2010. The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 39: 401–418, table of contents.
84. Ellison, T.I., M.K. Smith, A.C. Gilliam & P.N. Macdonald. 2008. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J. Invest. Dermatol. 128: 2508–2517.
85. 3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 127: 707–715.
86. Ma, Y., P. Zhang, F. Wang, et al. 2011. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol. 29: 3775–3782.
87. Yin, L., N. Grandi, E. Raum, et al. 2011. Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev. Med. 53: 10–16.
88. Cho, E., S.A. Smith-Warner, D. Spiegelman, et al. 2004. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J. Natl. Cancer Inst. 96: 1015–1022.
89. Carroll, C., K. Cooper, D. Papaioannou, et al. 2010. Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin. Ther. 32: 789–803.
90. Wactawski-Wende, J., J.M. Kotchen, G.L. Anderson, et al. 2006. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354: 684–696.
91. Shin, M.H., M.D. Holmes, S.E. Hankinson, et al. 2002. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J. Natl. Cancer Inst. 94: 1301–1311.
92. Lin, J., J.E. Manson, I.M. Lee, et al. 2007. Intakes of calcium and vitamin D and breast cancer risk in women. Arch. Intern. Med. 167: 1050–1059.
93. Chen, P., P. Hu, D. Xie, et al. 2010. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 121: 469–477.
94. Gandini, S., M. Boniol, J. Haukka, et al. 2011. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 128: 1414–1424.
95. van der Rhee, H.J., E. de Vries & J.W. Coebergh. 2006. Does sunlight prevent cancer? A systematic review. Eur. J. Cancer 42: 2222–2232.
96. Gilbert, R., R.M. Martin, R. Beynon, et al. 2011. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes Control 22: 319–340.
97. Scher, H.I., X. Jia, K. Chi, et al. 2011. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29: 2191–2198.
98. Tang, J.Y., N. Parimi, A. Wu, et al. 2010. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 21: 387–391.
99. Asgari, M.M., J. Tang, M.E. Warton, et al. 2010. Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. J. Invest. Dermatol. 130: 1438–1443.
100. Eide, M.J., D.A. Johnson, G.R. Jacobsen, et al. 2011. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch. Dermatol. 147: 1379–1384.
101. 3 is a negative endocrine regulator of the renin–angiotensin system. J. Clin. Invest. 110: 229–238.
102. 3-dependent regulation of the renin–angiotensin system in 1α-hydroxylase knockout mice. Kidney Int. 74: 170–179.
103. Andrukhova, O., S. Slavic, U. Zeitz, et al. 2014. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol. Endocrinol. 28: 53–64.
104. Ni, W., S.W. Watts, M. Ng, et al. 2014. Elimination of vitamin D receptor in vascular endothelial cells alters vascular function. Hypertension 64: 1290–1298.
105. 3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J. Clin. Invest. 97: 1577–1588.
106. 3 with cardiovascular function. III. Effects on physical and morphological properties. Am. J. Physiol. 258: E134–E142.
107. Xiang, W., J. Kong, S. Chen, et al. 2005. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin–angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288: E125–E132.
108. Chen, S., C.S. Law, C.L. Grigsby, et al. 2011. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124: 1838–1847.
109. Gardner, D.G., S. Chen & D.J. Glenn. 2013. Vitamin D and the heart. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305: R969–R977.
110. Rahman, A., S. Hershey, S. Ahmed, et al. 2007. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 103: 416–419.
111. Szeto, F.L., C.A. Reardon, D. Yoon, et al. 2012. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol. Endocrinol. 26: 1091–1101.
112. 3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler. Thromb. Vasc. Biol. 30: 2495–2503.
113. Choi, J.H., Q. Ke, S. Bae, et al. 2011. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J. Card. Fail. 17: 1051–1058.
114. Kong, J., G.H. Kim, M. Wei, et al. 2010. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am. J. Pathol. 177: 622–631.
115. Aihara, K., H. Azuma, M. Akaike, et al. 2004. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 279: 35798–35802.
116. 3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 102: 2867–2872.
117. Uysal, S., A.G. Kalayci & K. Baysal. 1999. Cardiac functions in children with vitamin D deficiency rickets. Pediatr. Cardiol. 20: 283–286.
118. Giovannucci, E., Y. Liu, B.W. Hollis & E.B. Rimm. 2008. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168: 1174–1180.
119. Wang, T.J., M.J. Pencina, S.L. Booth, et al. 2008. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503–511.
120. Marniemi, J., E. Alanen, O. Impivaara, et al. 2005. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr. Metab. Cardiovasc. Dis. 15: 188–197.
121. de Boer, I.H., B. Kestenbaum, A.B. Shoben, et al. 2009. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20: 1805–1812.
122. Carrelli, A.L., M.D. Walker, H. Lowe, et al. 2011. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke 42: 2240–2245.
123. Melamed, M.L., P. Muntner, E.D. Michos, et al. 2008. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler. Thromb. Vasc. Biol. 28: 1179–1185.
124. Messenger, W., C.M. Nielson, H. Li, et al. 2012. Serum and dietary vitamin D and cardiovascular disease risk in elderly men: a prospective cohort study. Nutr. Metab. Cardiovasc. Dis. 22: 856–863.
125. Wang, L., Y. Song, J.E. Manson, et al. 2012. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 5: 819–829.
126. Pittas, A.G., M. Chung, T. Trikalinos, et al. 2010. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152: 307–314.
127. Teng, M., M. Wolf, M.N. Ofsthun, et al. 2005. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16: 1115–1125.
128. Naves-Diaz, M., D. Alvarez-Hernandez, J. Passlick-Deetjen, et al. 2008. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 74: 1070–1078.
129. Burgaz, A., N. Orsini, S.C. Larsson & A. Wolk. 2011. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J. Hypertens. 29: 636–645.
130. Kunutsor, S.K., T.A. Apekey & M. Steur. 2013. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur. J. Epidemiol. 28: 205–221.
131. Wang, T.J., F. Zhang, J.B. Richards, et al. 2010. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180–188.
132. Vimaleswaran, K.S., A. Cavadino, D.J. Berry, et al. 2014. Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2: 719–729.
133. Sugden, J.A., J.I. Davies, M.D. Witham, et al. 2008. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25: 320–325.
134. Thadhani, R., E. Appelbaum, Y. Pritchett, et al. 2012. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307: 674–684.
135. Elamin, M.B., N.O. Abu Elnour, K.B. Elamin, et al. 2011. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96: 1931–1942.
136. Rejnmark, L., A. Avenell, T. Masud, et al. 2012. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J. Clin. Endocrinol. Metab. 97: 2670–2681.
137. 3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 134: 1602–1610.
138. 3-1α-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 89–90: 121–125.
139. 3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119: 84–90.
140. 3 and the analogues MC903 and KH1060 on interleukin-1β-induced inhibition of rat pancreatic islet β-cell function in vitro. Immunol. Lett. 41: 73–77.
141. Wolden-Kirk, H., L. Overbergh, H.T. Christesen, et al. 2011. Vitamin D and diabetes: its importance for beta cell and immune function. Mol. Cell. Endocrinol. 347: 106–120.
142. Norman, A.W., J.B. Frankel, A.M. Heldt & G.M. Grodsky. 1980. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209: 823–825.
143. Zeitz, U., K. Weber, D.W. Soegiarto, et al. 2003. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 17: 509–511.
144. Hagstrom, E., P. Hellman, E. Lundgren, et al. 2007. Serum calcium is independently associated with insulin sensitivity measured with euglycaemic–hyperinsulinaemic clamp in a community-based cohort. Diabetologia 50: 317–324.
145. Gysemans, C., E. van Etten, L. Overbergh, et al. 2008. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 57: 269–275.
146. Cheng, Q., Y.C. Li, B.J. Boucher & P.S. Leung. 2011. A novel role for vitamin D: modulation of expression and function of the local renin–angiotensin system in mouse pancreatic islets. Diabetologia 54: 2077–2081.
147. Mezza, T., G. Muscogiuri, G.P. Sorice, et al. 2012. Vitamin D deficiency: a new risk factor for type 2 diabetes? Ann. Nutr. Metab. 61: 337–348.
148. Forouhi, N.G., Z. Ye, A.P. Rickard, et al. 2012. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 55: 2173–2182.
149. Song, Y., L. Wang, A.G. Pittas, et al. 2013. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 36: 1422–1428.
150. Khan, H., S. Kunutsor, O.H. Franco & R. Chowdhury. 2013. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc. Nutr. Soc. 72: 89–97.
151. Lim, S., M.J. Kim, S.H. Choi, et al. 2013. Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. Am. J. Clin. Nutr. 97: 524–530.
152. Scragg, R., M. Sowers, C. Bell; Third National Health and Nutrition Examination Survey. 2004. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27: 2813–2818.
153. Grimnes, G., N. Emaus, R.M. Joakimsen, et al. 2010. Baseline serum 25-hydroxyvitamin D concentrations in the Tromsø Study 1994–95 and risk of developing type 2 diabetes mellitus during 11 years of follow-up. Diabet. Med. 27: 1107–1115.
154. Belenchia, A.M., A.K. Tosh, L.S. Hillman & C.A. Peterson. 2013. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. Am. J. Clin. Nutr. 97: 774–781.
155. Harris, S.S., A.G. Pittas & N.J. Palermo. 2012. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes. Metab. 14: 789–794.
156. 3 in 3T3-L1 preadipocytes. Biochem. Biophys. Res. Commun. 193: 948–955.
157. Querfeld, U., M.M. Hoffmann, G. Klaus, et al. 1999. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J. Am. Soc. Nephrol. 10: 2158–2164.
158. Li, J., M.E. Byrne, E. Chang, et al. 2008. 1α, 25-Dihydroxyvitamin D hydroxylase in adipocytes. J. Steroid Biochem. Mol. Biol. 112: 122–126.
159. Bikle, D.D. 2012. Vitamin D and bone. Curr. Osteoporos. Rep. 10: 151–159.
160. 3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J. Cell. Physiol. 228: 2024–2036.
161. 3 promote the differentiation of human subcutaneous preadipocytes. PLoS One 7: e52171.
162. 3 are mediated by the maintenance of the wingless-type MMTV integration site/β-catenin pathway. Int. J. Mol. Med. 30: 1219–1224.
163. Blumberg, J.M., I. Tzameli, I. Astapova, et al. 2006. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J. Biol. Chem. 281: 11205–11213.
164. Malloy, P.J. & B.J. Feldman. 2013. Cell-autonomous regulation of brown fat identity gene UCP1 by unliganded vitamin D receptor. Mol. Endocrinol. 27: 1632–1642.
165. Narvaez, C.J., D. Matthews, E. Broun, et al. 2009. Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology 150: 651–661.
166. Wong, K.E., J. Kong, W. Zhang, et al. 2011. Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J. Biol. Chem. 286: 33804–33810.
167. Earthman, C.P., L.M. Beckman, K. Masodkar & S.D. Sibley. 2012. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int. J. Obes. (Lond.) 36: 387–396.
168. Drincic, A.T., L.A. Armas, E.E. Van Diest & R.P. Heaney. 2012. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring) 20: 1444–1448.
169. Wortsman, J., L.Y. Matsuoka, T.C. Chen, et al. 2000. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72: 690–693.
170. Soares, M.J., W. Chan She Ping-Delfos & M.H. Ghanbari. 2011. Calcium and vitamin D for obesity: a review of randomized controlled trials. Eur. J. Clin. Nutr. 65: 994–1004.
171. Boon, N., G.B. Hul, A. Sicard, et al. 2006. The effects of increasing serum calcitriol on energy and fat metabolism and gene expression. Obesity (Silver Spring) 14: 1739–1746.
172. Peterson, L.A., X. Zeng, C.P. Caufield-Noll, et al. 2016. Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review. Surg. Obes. Relat. Dis. 12: 693–702.
173. Rueda, S., C. Fernandez-Fernandez, F. Romero, et al. 2008. Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes. Surg. 18: 151–154.
174. 3 in human skeletal muscle precursor cells. Endocrinology 157: 98–111.
175. Wang, Y. & H.F. DeLuca. 2011. Is the vitamin D receptor found in muscle? Endocrinology 152: 354–363.
176. Girgis, C.M., N. Mokbel, K.M. Cha, et al. 2014. The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. Endocrinology 155: 3227–3237.
177. Girgis, C.M., R.J. Clifton-Bligh, N. Mokbel, et al. 2014. Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells. Endocrinology 155: 347–357.
178. Boland, R.L. 2011. VDR activation of intracellular signaling pathways in skeletal muscle. Mol. Cell. Endocrinol. 347: 11–16.
179. Girgis, C.M., R.J. Clifton-Bligh, M.W. Hamrick, et al. 2013. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr. Rev. 34: 33–83.
180. 3 stimulate the skeletal muscle-calcium mobilization in rachitic chicks. Arch. Biochem. Biophys. 231: 211–216.
181. 3-induced SOC influx in muscle cells. Int. J. Biochem. Cell Biol. 36: 1910–1918.
182. 3 induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. J. Cell. Biochem. 86: 128–135.
183. Annweiler, C., A.M. Schott, M. Montero-Odasso, et al. 2010. Cross-sectional association between serum vitamin D concentration and walking speed measured at usual and fast pace among older women: the EPIDOS study. J. Bone Miner. Res. 25: 1858–1866.
184. Bhat, M., R. Kalam, S.S. Qadri, et al. 2013. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. Endocrinology 154: 4018–4029.
185. Thomas, M.K., D.M. Lloyd-Jones, R.I. Thadhani, et al. 1998. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338: 777–783.
186. Latham, N.K., C.S. Anderson & I.R. Reid. 2003. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J. Am. Geriatr. Soc. 51: 1219–1226.
187. Bischoff-Ferrari, H.A., B. Dawson-Hughes, H.B. Staehelin, et al. 2009. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339: b3692.
188. Murad, M.H., K.B. Elamin, N.O. Abu Elnour, et al. 2011. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96: 2997–3006.
189. Knutsen, K.V., A.A. Madar, P. Lagerlov, et al. 2014. Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway. J. Clin. Endocrinol. Metab. 99: 194–202.
190. Bolland, M.J., A. Grey, G.D. Gamble & I.R. Reid. 2014. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes—authors' reply. Lancet Diabetes Endocrinol. 2: 364–365.
191. Sinha, A., K.G. Hollingsworth, S. Ball & T. Cheetham. 2013. Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J. Clin. Endocrinol. Metab. 98: E509–E513.
192. Sanders, K.M., A.L. Stuart, E.J. Williamson, et al. 2010. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303: 1815–1822.
193. Bischoff-Ferrari, H.A., B. Dawson-Hughes, E.J. Orav, et al. 2016. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern. Med. 176: 175–183.
194. Bikle, D.D. 2012. Vitamin D and the skin: physiology and pathophysiology. Rev. Endocr. Metab. Disord. 13: 3–19.
195. Lehmann, B. & M. Meurer. 2003. Extrarenal sites of calcitriol synthesis: the particular role of the skin. Recent Results Cancer Res. 164: 135–145.
196. Cheng, J.B., D.L. Motola, D.J. Mangelsdorf & D.W. Russell. 2003. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J. Biol. Chem. 278: 38084–38093.
197. 3. Biochemistry 25: 1545–1548.
198. Pillai, S., D.D. Bikle & P.M. Elias. 1988. 1,25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. J. Biol. Chem. 263: 5390–5395.
199. Li, Y.C., A.E. Pirro, M. Amling, et al. 1997. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci. U.S.A. 94: 9831–9835.
200. Yoshizawa, T., Y. Handa, Y. Uematsu, et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16: 391–396.
201. Malloy, P.J., J.W. Pike & D. Feldman. 1999. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev. 20: 156–188.
202. Bikle, D.D., S. Chang, D. Crumrine, et al. 2004. 25 Hydroxyvitamin D 1 α-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J. Invest. Dermatol. 122: 984–992.
203. Malloy, P.J. & D. Feldman. 2010. Genetic disorders and defects in vitamin D action. Endocrinol. Metab. Clin. North Am. 39: 333–346, table of contents.
204. Lien, W.H., L. Polak, M. Lin, et al. 2014. In vivo transcriptional governance of hair follicle stem cells by canonical Wnt regulators. Nat. Cell Biol. 16: 179–190.
205. Choi, Y.S., Y. Zhang, M. Xu, et al. 2013. Distinct functions for Wnt/β-catenin in hair follicle stem cell proliferation and survival and interfollicular epidermal homeostasis. Cell Stem Cell 13: 720–733.
206. Lim, X., S.H. Tan, W.L. Koh, et al. 2013. Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. Science 342: 1226–1230.
207. Shah, S., M.N. Islam, S. Dakshanamurthy, et al. 2006. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol. Cell 21: 799–809.
208. Palmer, H.G., F. Anjos-Afonso, G. Carmeliet, et al. 2008. The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS One 3: e1483.
209. Cianferotti, L., M. Cox, K. Skorija & M.B. Demay. 2007. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl. Acad. Sci. U.S.A. 104: 9428–9433.
210. Hawker, N.P., S.D. Pennypacker, S.M. Chang & D.D. Bikle. 2007. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J. Invest. Dermatol. 127: 874–880.
211. Oda, Y., Y. Uchida, S. Moradian, et al. 2009. Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation. J. Invest. Dermatol. 129: 1367–1378.
212. Oda, Y., R.J. Chalkley, A.L. Burlingame & D.D. Bikle. 2010. The transcriptional coactivator DRIP/mediator complex is involved in vitamin D receptor function and regulates keratinocyte proliferation and differentiation. J. Invest. Dermatol. 130: 2377–2388.
213. Oda, Y., L. Hu, V. Bul, et al. 2012. Coactivator MED1 ablation in keratinocytes results in hair-cycling defects and epidermal alterations. J. Invest. Dermatol. 132: 1075–1083.
214. Bikle, D.D., Z. Xie & C.L. Tu. 2012. Calcium regulation of keratinocyte differentiation. Expert Rev. Endocrinol. Metab. 7: 461–472.
215. Oda, Y., C.L. Tu, S. Pillai & D.D. Bikle. 1998. The calcium sensing receptor and its alternatively spliced form in keratinocyte differentiation. J. Biol. Chem. 273: 23344–23352.
216. Tu, C.L., W. Chang & D.D. Bikle. 2001. The extracellular calcium-sensing receptor is required for calcium-induced differentiation in human keratinocytes. J. Biol. Chem. 276: 41079–41085.
217. Tu, C.L., D.A. Crumrine, M.Q. Man, et al. 2012. Ablation of the calcium-sensing receptor in keratinocytes impairs epidermal differentiation and barrier function. J. Invest. Dermatol. 132: 2350–2359.
218. Oda, Y., C.L. Tu, A. Menendez, et al. 2015. Vitamin D and calcium regulation of epidermal wound healing. J. Steroid Biochem. Mol. Biol. pii: S0960-0760(15)30048-0. DOI: 10.1016/j.jsbmb.2015.08.011.
219. Bikle, D.D. 2015. Vitamin D receptor, a tumor suppressor in skin. Can. J. Physiol. Pharmacol. 93: 349–354.
220. Schon, M.P. & W.H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899–1912.
221. 3) for the treatment of psoriasis. Br. J. Dermatol. 134: 238–246.
222. 3 analogue (MC 903) in a double-blind study. Br. J. Dermatol. 119: 223–230.
223. van de Kerkhof, P.C., J. Berth-Jones, C.E. Griffiths, et al. 2002. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br. J. Dermatol. 146: 414–422.
224. Barker, J.N., R.E. Ashton, R. Marks, et al. 1999. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br. J. Dermatol. 141: 274–278.
225. Schauber, J., R.A. Dorschner, A.B. Coda, et al. 2007. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117: 803–811.
226. Debinska, A., H. Sikorska-Szaflik, M. Urbanik & A. Boznanski. 2015. The role of vitamin D in atopic dermatitis. Dermatitis 26: 155–161.
227. Ingen-Housz-Oro, S., P. Boudou, C. Bergot, et al. 2006. Evidence of a marked 25-hydroxyvitamin D deficiency in patients with congenital ichthyosis. J. Eur. Acad. Dermatol. Venereol. 20: 947–952.
228. Thacher, T.D., P.R. Fischer, J.M. Pettifor & G.L. Darmstadt. 2004. Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics 114: e119–e123.
229. Liu, P.T., S.R. Krutzik & R.L. Modlin. 2007. Therapeutic implications of the TLR and VDR partnership. Trends Mol. Med. 13: 117–124.
230. Bikle, D.D. 2009. Vitamin D and immune function: understanding common pathways. Curr. Osteoporos. Rep. 7: 58–63.
231. 3 on human B cell differentiation. J. Immunol. 179: 1634–1647.
232. 3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8: 285–293.
233. Bikle, D.D., S. Pillai, E. Gee & M. Hincenbergs. 1989. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-γ. Endocrinology 124: 655–660.
234. Bikle, D.D., S. Pillai, E. Gee & M. Hincenbergs. 1991. Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology 129: 33–38.
235. Pryke, A.M., C. Duggan, C.P. White, et al. 1990. Tumor necrosis factor-alpha induces vitamin D-1-hydroxylase activity in normal human alveolar macrophages. J. Cell. Physiol. 142: 652–656.
236. Gyetko, M.R., C.H. Hsu, C.C. Wilkinson, et al. 1993. Monocyte 1 alpha–hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J. Leukoc. Biol. 54: 17–22.
237. Ren, S., L. Nguyen, S. Wu, et al. 2005. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem. 280: 20604–20611.
238. Vidal, M., C.V. Ramana & A.S. Dusso. 2002. Stat1–vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol. Cell. Biol. 22: 2777–2787.
239. 3: basic concepts. J. Steroid Biochem. Mol. Biol. 97: 93–101.
240. Daniel, C., N.A. Sartory, N. Zahn, et al. 2008. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 324: 23–33.
241. 3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 31: 3653–3669.
242. 3 on the development of effector CD4 T cells. J. Biol. Chem. 286: 997–1004.
243. Keating, P., A. Munim & J.X. Hartmann. 2014. Effect of vitamin D on T-helper type 9 polarized human memory cells in chronic persistent asthma. Ann. Allergy Asthma Immunol. 112: 154–162.
244. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167: 1945–1953.
245. Sakaguchi, S., T. Yamaguchi, T. Nomura & M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775–787.
246. 3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol. Cell. Biol. 15: 5789–5799.
247. 3: a transcriptional modulator of the interferon-γ gene. Eur. J. Immunol. 28: 3017–3030.
248. Riis, J.L., C. Johansen, B. Gesser, et al. 2004. 1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch. Dermatol. Res. 296: 195–202.
249. Dong, X., W. Lutz, T.M. Schroeder, et al. 2005. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc. Natl. Acad. Sci. U.S.A. 102: 16007–16012.
250. Mathieu, C., E. Van Etten, C. Gysemans, et al. 2001. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J. Bone Miner. Res. 16: 2057–2065.
251. Adorini, L. & G. Penna. 2008. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404–412.
252. Amuchastegui, S., K.C. Daniel & L. Adorini. 2005. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 80: 81–87.
253. Zhang, Z., P. Hener, N. Frossard, et al. 2009. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc. Natl. Acad. Sci. U.S.A. 106: 1536–1541.
254. 3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur. J. Immunol. 34: 1068–1076.
255. Wittke, A., V. Weaver, B.D. Mahon, et al. 2004. Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J. Immunol. 173: 3432–3436.
256. Bieber, T. 2008. Atopic dermatitis. N. Engl. J. Med. 358: 1483–1494.
257. Hartmann, B., R. Riedel, K. Jorss, et al. 2012. Vitamin D receptor activation improves allergen-triggered eczema in mice. J. Invest. Dermatol. 132: 330–336.
258. Ehrchen, J., L. Helming, G. Varga, et al. 2007. Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. FASEB J. 21: 3208–3218.
259. Khader, S.A., S.L. Gaffen & J.K. Kolls. 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2: 403–411.
260. 3 induces splenocyte apoptosis and enhances BALB/c mice sensitivity to toxoplasmosis. J. Steroid Biochem. Mol. Biol. 96: 179–185.
261. 3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses. Am. J. Physiol. Gastrointest. Liver Physiol. 303: G1299–G1311.
262. Ascherio, A., K.L. Munger & K.C. Simon. 2010. Vitamin D and multiple sclerosis. Lancet Neurol. 9: 599–612.
263. Knip, M., S.M. Virtanen & H.K. Akerblom. 2010. Infant feeding and the risk of type 1 diabetes. Am. J. Clin. Nutr. 91: 1506S–1513S.
264. Littorin, B., P. Blom, A. Scholin, et al. 2006. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49: 2847–2852.
265. Cantorna, M.T. 2006. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol. 92: 60–64.
266. Lee, Y.H. & S.C. Bae. 2016. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clin. Exp. Rheumatol. Apr 6. Epub ahead of print.
267. Kamen, D. & C. Aranow. 2008. Vitamin D in systemic lupus erythematosus. Curr. Opin. Rheumatol. 20: 532–537.
268. Goswami, R., R.K. Marwaha, N. Gupta, et al. 2009. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br. J. Nutr. 102: 382–386.
269. Chiu, C.Y., S.Y. Huang, Y.C. Peng, et al. 2015. Maternal vitamin D levels are inversely related to allergic sensitization and atopic diseases in early childhood. Pediatr. Allergy Immunol. 26: 337–343.
270. Black, P.N. & R. Scragg. 2005. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest 128: 3792–3798.
271. Quirk, S.K., E. Rainwater, A.K. Shure & D.K. Agrawal. 2016. Vitamin D in atopic dermatitis, chronic urticaria and allergic contact dermatitis. Expert Rev. Clin. Immunol. 12: 839–847.
272. 3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 311: 2083–2091.
273. Yang, J., L. Liu, Q. Zhang, et al. 2015. Effect of vitamin D on the recurrence rate of rheumatoid arthritis. Exp. Ther. Med. 10: 1812–1816.
274. Bizzarri, C., D. Pitocco, N. Napoli, et al. 2010. No protective effect of calcitriol on β-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 33: 1962–1963.
275. Kim, G. & J.H. Bae. 2016. Vitamin D and atopic dermatitis: a systematic review and meta-analysis. Nutrition 32: 913–920.
276. Liu, P.T., S. Stenger, H. Li, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770–1773.
277. Schauber, J. & R.L. Gallo. 2008. The vitamin D pathway: a new target for control of the skin's immune response? Exp. Dermatol. 17: 633–639.
278. 3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57: 159–163.
279. Adams, J.S., S. Ren, P.T. Liu, et al. 2009. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 182: 4289–4295.
280. Davies, P.D., R.C. Brown & J.S. Woodhead. 1985. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 40: 187–190.
281. Brightbill, H.D., D.H. Libraty, S.R. Krutzik, et al. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285: 732–736.
282. Lande, R., J. Gregorio, V. Facchinetti, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564–569.
283. Ong, P.Y., T. Ohtake, C. Brandt, et al. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347: 1151–1160.
284. 3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377: 242–250.
285. Salahuddin, N., F. Ali, Z. Hasan, et al. 2013. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect. Dis. 13: 22.
286. Daley, P., V. Jagannathan, K.R. John, et al. 2015. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 15: 528–534.
287. 3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. Am. J. Clin. Nutr. 102: 1059–1069.